Asterias Biotherapeutics Inc (AST) COO Sells $19,649.91 in Stock
Asterias Biotherapeutics Inc (NYSEMKT:AST) COO Katharine E. Spink sold 4,781 shares of the stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $4.11, for a total transaction of $19,649.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Katharine E. Spink also recently made the following trade(s):
- On Friday, September 9th, Katharine E. Spink sold 19,336 shares of Asterias Biotherapeutics stock. The stock was sold at an average price of $3.52, for a total transaction of $68,062.72.
Shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) opened at 3.88 on Wednesday. The stock’s 50 day moving average is $3.75 and its 200 day moving average is $3.50. Asterias Biotherapeutics Inc has a 12 month low of $2.30 and a 12 month high of $5.75. The firm’s market cap is $176.22 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/asterias-biotherapeutics-inc-ast-coo-sells-19649-91-in-stock.html
Asterias Biotherapeutics (NYSEMKT:AST) last announced its earnings results on Monday, August 15th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The firm earned $1.53 million during the quarter, compared to analyst estimates of $1.14 million. On average, analysts anticipate that Asterias Biotherapeutics Inc will post ($0.73) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares during the last quarter. BlackRock Investment Management LLC increased its position in shares of Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares during the last quarter. State Street Corp increased its position in shares of Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares during the last quarter. Sabby Management LLC purchased a new position in shares of Asterias Biotherapeutics during the second quarter valued at $741,000. Finally, BlackRock Fund Advisors increased its position in shares of Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares during the last quarter.
AST has been the subject of several research analyst reports. FBR & Co reaffirmed a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, September 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Asterias Biotherapeutics in a research note on Sunday, September 11th. Finally, Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Thursday, August 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Asterias Biotherapeutics presently has an average rating of “Buy” and an average price target of $7.75.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.